In a filing to Shanghai's stock exchange, CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca. It did not disclose the value of the deal. AstraZeneca said the deal would support investigational mRNA vaccines in its early pipeline.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment